Collection 2 (Sep 2021 - Aug 2022) Articles

Articles
Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines
Mortensen MB, Tybjærg-Hansen A, Nordestgaard BG
Journal:
JAMA Cardiol

First published: July 6, 2022 DOI: 10.1001/jamacardio.2022.1876
View
- Share
Articles
Highlights in ASCVD Primary Prevention for 2021
Polonsky TS, Khera A, Miedema MD, et al.
Journal:
J Am Heart Assoc

First published: July 4, 2022 DOI: 10.1161/JAHA.122.025973
View
- Share
Articles
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Hagström E, Steg PG, Szarek M, et al.
Journal:
Circulation

First published: June 30, 2022 DOI: 10.1161/CIRCULATIONAHA.121.057807
View
- Share
Articles
Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia
Gitt AK, Laufs U, März W, et al.
Journal:
J Clin Med

First published: June 30, 2022 DOI: 10.3390/jcm11133810
View
- Share
Articles
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy
Ridker PM, Rifai N, MacFadyen J, et al.
Journal:
Circulation

First published: June 28, 2022 DOI: 10.1161/CIRCULATIONAHA.122.059410
View
- Share
Articles
Small interfering ribonucleic acid for cholesterol lowering – Inclisiran: Inclisiran for cholesterol lowering
Soffer D, Stoekenbroek R, Plakogiannis R
Journal:
J Clin Lipidol

First published: June 28, 2022 DOI: 10.1016/j.jacl.2022.06.009
View
- Share
Articles
Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial
Hori M, Zhu J, Liang Y, et al.
Journal:
Eur Heart J

First published: June 25, 2022 DOI: 10.1093/eurheartj/ehac309
View
- Share
Articles
Association Between Familial Hypercholesterolemia and Risk of Cardiovascular Events and Death in Different Cohorts: A Meta-Analysis of 1.1 Million Subjects
Yu Y, Chen L, Zhang H, et al.
Journal:
Front Cardiovasc Med

First published: June 21, 2022 DOI: 10.3389/fcvm.2022.860196
View
- Share
Articles
Causes, Angiographic Characteristics, and Management of Premature Myocardial Infarction: JACC State-of-the-Art Review
Rallidis LS, Xenogiannis I, Brilakis ES, et al.
Journal:
J Am Coll Cardiol

First published: June 21, 2022 DOI: 10.1016/j.jacc.2022.04.015
View
- Share
Articles
Omega-3 fatty acids, subclinical atherosclerosis, and cardiovascular events: Implications for primary prevention
Alfaddagh A, Kapoor K, Dardari ZA, et al.
Journal:
Atherosclerosis

First published: June 20, 2022 DOI: 10.1016/j.atherosclerosis.2022.06.1018
View
- Share
Articles
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab
Landmesser U, McGinniss J, Steg PG, et al.
Journal:
Eur J Prev Cardiol

First published: June 16, 2022 DOI: 10.1093/eurjpc/zwac107
View
- Share
Articles
Chasing LDL cholesterol to the bottom — PCSK9 in perspective
Libby P, Tokgözoğlu L
Journal:
Nat Cardiovasc Res

First published: June 15, 2022 DOI: 10.1038/s44161-022-00085-x
View
- Share

1 2 3 4 5 … 14

Collection 2 (Sep 2021 - Aug 2022) Articles

Articles

Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines

Mortensen MB, Tybjærg-Hansen A, Nordestgaard BG

Articles

Highlights in ASCVD Primary Prevention for 2021

Polonsky TS, Khera A, Miedema MD, et al.

Articles

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström E, Steg PG, Szarek M, et al.

Articles

Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia

Gitt AK, Laufs U, März W, et al.

Articles

Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy

Ridker PM, Rifai N, MacFadyen J, et al.

Articles

Small interfering ribonucleic acid for cholesterol lowering – Inclisiran: Inclisiran for cholesterol lowering

Soffer D, Stoekenbroek R, Plakogiannis R

Articles

Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial

Hori M, Zhu J, Liang Y, et al.

Articles

Association Between Familial Hypercholesterolemia and Risk of Cardiovascular Events and Death in Different Cohorts: A Meta-Analysis of 1.1 Million Subjects

Yu Y, Chen L, Zhang H, et al.

Articles

Causes, Angiographic Characteristics, and Management of Premature Myocardial Infarction: JACC State-of-the-Art Review

Rallidis LS, Xenogiannis I, Brilakis ES, et al.

Articles

Omega-3 fatty acids, subclinical atherosclerosis, and cardiovascular events: Implications for primary prevention

Alfaddagh A, Kapoor K, Dardari ZA, et al.

Articles

Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab

Landmesser U, McGinniss J, Steg PG, et al.

Articles

Chasing LDL cholesterol to the bottom — PCSK9 in perspective

Libby P, Tokgözoğlu L

Articles

Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines

Mortensen MB, Tybjærg-Hansen A, Nordestgaard BG

Share

Articles

Highlights in ASCVD Primary Prevention for 2021

Polonsky TS, Khera A, Miedema MD, et al.

Share

Articles

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström E, Steg PG, Szarek M, et al.

Share

Articles

Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia

Gitt AK, Laufs U, März W, et al.

Share

Articles

Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy

Ridker PM, Rifai N, MacFadyen J, et al.

Share

Articles

Small interfering ribonucleic acid for cholesterol lowering – Inclisiran: Inclisiran for cholesterol lowering

Soffer D, Stoekenbroek R, Plakogiannis R

Share

Articles

Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial

Hori M, Zhu J, Liang Y, et al.

Share

Articles

Association Between Familial Hypercholesterolemia and Risk of Cardiovascular Events and Death in Different Cohorts: A Meta-Analysis of 1.1 Million Subjects

Yu Y, Chen L, Zhang H, et al.

Share

Articles

Causes, Angiographic Characteristics, and Management of Premature Myocardial Infarction: JACC State-of-the-Art Review

Rallidis LS, Xenogiannis I, Brilakis ES, et al.

Share

Articles

Omega-3 fatty acids, subclinical atherosclerosis, and cardiovascular events: Implications for primary prevention

Alfaddagh A, Kapoor K, Dardari ZA, et al.

Share

Articles

Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab

Landmesser U, McGinniss J, Steg PG, et al.

Share

Articles

Chasing LDL cholesterol to the bottom — PCSK9 in perspective

Libby P, Tokgözoğlu L

Share